Join the club for FREE to access the whole archive and other member benefits.

James Peyer

Stem cell biologist out to build biotech companies focused on age-related diseases, CEO at Cambrian Biopharma

James Peyer, PhD is the Founder and CEO of a stealth-mode diversified pharmaceutical R&D holding company developing therapeutics targeting the biology of aging (‘geroscience’). The New York-based company builds, finances, and manages biotech companies. Dr. Peyer founded the company to translate laboratory breakthroughs in the extension of healthy lifespan into the clinic, predicting that the world is entering a revolution in biomedical research by targeting the root causes of aging and age-related disease.

Dr. Peyer has spoken on the topic of longevity biotech and investing for The Economist, TEDx, Longevity Leaders, ETH Zurich, and the Max Planck Institute on the Biology of Aging, to advance the mission of achieving widespread availability of longevity therapeutics this decade.

Before his current role, James was Founder and Managing Partner at Apollo Ventures, one of the major longevity-focused venture capital firms. Apollo has deployed over $20M and raised over $50M in the first three years of operations. He led investments in Cleara Biotech, Aeovian Pharmaceuticals, and Samsara Therapeutics and served on the Board and/or in executive roles for all three companies.

Visit website:



See also: Company Cambrian Biopharma - A distributed drug discovery company

Details last updated 24-Jan-2020

James Peyer is also referenced in the following:

Age-Related Disease Therapeutics Summit

31-May-2023 to 02-Jun-2023

Event about aging and aging related diseases organized by Hanson Wade

ARDD 2023 - 10th Aging Research & Drug Discovery Meeting

28-Aug-2023 to 01-Sep-2023

Event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen

Metabesity 2021

11-Oct-2021 to 14-Oct-2021

The Kitalys institute virtual conference targeting key questions that will impact the future of aging and extending healthspan

James Peyer News

Telos Biotech parent, Cambrian Bio, to develop robust cell therapies for treating age-related diseases

Longevity Technology - 27-Jun-2023

Novel recombinant protein to manufacture biologically fit cells by safely lengthening telomeres


Reason reports back from Age-Related Disease Therapeutics Summit 2023

Fight Aging! - 16-Jun-2023

Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few years


Vita Therapeutics raised $31m to develop treatment for genetic diseases and cancers

Business Wire - 12-Oct-2022

Cell therapies aiming not only to correct the genetic defect but also repair and heal the muscle cells


A proactive step for next generation drug discovery by Cambrian Biopharma

Longevity Technology - 26-Oct-2021

Novel business approach helps people to live longer with good health


Cambrian Biopharma raised $60 million in stealth mode

Longevity Technology - 09-Feb-2021

New York-based biotech company with unique approaches to treat age-related diseases


Cleara Biotech Joins the Race to Develop Senolytic Therapies (LEAF) - 09-Jul-2018

This therapy uses a modified FOXO4 to promote apoptosis in senescent cells